Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,521 signal articles · 30 in last 24h · 122,251 total before filter · latest 35m ago
30last 24h
1259last 7d
213● bullish (7d)
150● bearish (7d)
205publishers
AllMacro211Earnings431M&A96Regulatory23Product9Analyst11
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
NuScale Power (SMR) Is Down 15.5% After Q1 Revenue Plunge And Wider Losses - Has The Bull Case Changed?
Simply Wall St.96d agobearish
NuScale Power (SMR) Is Down 15.5% After Q1 Revenue Plunge And Wider Losses - Has The Bull Case Changed?

In the past quarter, NuScale Power reported Q1 2026 sales of US$565,000 versus US$13.38 million a year earlier, with net loss widening to US$44.02 million and basic loss per share from continuing operations rising to US$0.14. At the same time, NuScale is pressing ahead with large-scale SMR commercialization efforts and facing heightened legal scrutiny over alleged misleading partnership disclosures, creating a complex mix of operational progress and risk for investors to weigh. Next, we’ll...

Investing.com96d agobearish
Seagate stock Falls 7.5% as CEO rejects factory expansion plans

Investing.com -- Seagate Technology Holdings (NASDAQ:STX) shares fell 7.5% Monday after Chief Executive Officer Dave Mosley said building new factories would "take too long" during a presentation at the JPMorgan Global Technology, Media and Communications Conference.

Starbucks delivers tough update on regional offices, cuts 100s of jobs
TheStreet96d agobearish
Starbucks delivers tough update on regional offices, cuts 100s of jobs

Starbucks is trying to bring customers back to its coffeehouses, but the company’s turnaround is coming at the cost of yet another painful message for its workers. Away from the coffee houses, this time the Seattle-based coffee giant is going for corporate jobs and closing several regional support ...

BofA Slaps Salesforce With Underperform Rating, $160 Price Target: Is the AI Story Falling Flat?
24/7 Wall St.96d agobearish
BofA Slaps Salesforce With Underperform Rating, $160 Price Target: Is the AI Story Falling Flat?

Bank of America (NYSE:BAC) just made one of the more contrarian calls on Wall Street regarding the enterprise software giant. Analyst Tal Liani reinstated coverage of Salesforce (NYSE:CRM) with an Underperform rating and a $160 price target, a notable bear take on a stock that still carries a consensus average price target of $268.05. For ... BofA Slaps Salesforce With Underperform Rating, $160 Price Target: Is the AI Story Falling Flat?

Citi Calls the Aerospace Selloff a Gift, Raises Boeing Price Target to $260
24/7 Wall St.96d agobearish
Citi Calls the Aerospace Selloff a Gift, Raises Boeing Price Target to $260

A major analyst just offered a bull case for Boeing (NYSE:BA) stock, framing the recent aerospace selloff as a buying window for patient investors. Citi raised its price target on Boeing to $260 from $256 and reiterated a Buy rating, with the firm telling clients the real opportunity lies in the dislocation itself. The call ... Citi Calls the Aerospace Selloff a Gift, Raises Boeing Price Target to $260

FuelCell Energy Slumps 22%, Plug Power Sinks 12%: Hydrogen Bulls Hit the Brakes
24/7 Wall St.96d agobearish
FuelCell Energy Slumps 22%, Plug Power Sinks 12%: Hydrogen Bulls Hit the Brakes

Shares of FuelCell Energy (NASDAQ:FCEL) slid 22% in Monday morning trading, while Plug Power (NASDAQ:PLUG) shares dropped 12%. The selloff hits two of the loudest winners of the AI power trade. The hydrogen rally is taking a breather after weeks of euphoric upside. The pullback comes after a remarkable run. FuelCell Energy stock has surged ... FuelCell Energy Slumps 22%, Plug Power Sinks 12%: Hydrogen Bulls Hit the Brakes

Regeneron Stock Tumbles on Melanoma Drug-Trial Miss
The Wall Street Journal96d agobearish
Regeneron Stock Tumbles on Melanoma Drug-Trial Miss

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

Jefferies Warns Mobileye Shares Could Fall 24% on Structural Challenges (MBLY)
InvestorsHub96d agobearish
Jefferies Warns Mobileye Shares Could Fall 24% on Structural Challenges (MBLY)

Jefferies Starts Coverage With Underperform RatingMobileye Global (NASDAQ:MBLY) faces potential downside risks tied to structural industry challenges and customer concentration, according to Jefferies, which initiated coverage on the stock with an “underperform” rating and an $8 price target. The target implies roughly 24% downside from the stock’s previous closing price of $10.

Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead
24/7 Wall St.96d agobearish
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Michael Burry Says Today’s Top 10 Stocks Surged 784% in a Year. The Pre-Dot-Com Number Was 622%.
24/7 Wall St.96d agobearish
Michael Burry Says Today’s Top 10 Stocks Surged 784% in a Year. The Pre-Dot-Com Number Was 622%.

My children often tell me that “today” is the best or worst day ever. Sometimes both land on the same day. Apparently it is possible to have the worst day ever multiple times a week. Unrelated. The benchmark S&P 500 keeps tagging fresh records and the tech-heavy Nasdaq Composite refuses to roll over. And yet ... Michael Burry Says Today’s Top 10 Stocks Surged 784% in a Year. The Pre-Dot-Com Number Was 622%.

Investing.com96d agobearish
Strategy drops $2 billion in epic bitcoin buying spree

Investing.com -- In one of the most aggressive corporate treasury maneuvers of the year, Strategy Inc. (NASDAQ:MSTR) successfully raised $2.03 billion through targeted stock sales last week, immediately deploying the capital to purchase an additional 24,869 bitcoin.